Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial

Completed · Phase 3

Conditions studied: Prostatic Neoplasm

In brief

The purpose of this study is to determine the most appropriate radiation implant dose for palladium-103 monotherapy. Radiation dose is related to potential cure. From previously published studies, it appears that the prescribed radiation dose can be reduced by 14-20% without any difference in potential cure (in this study, the dose is being decreased 10%). Although most patients tolerate brachytherapy well, complications to appear to be related to radiation exposure to normal structures (i.e. urethra, rectum and proximal penis). By reducing the prescribed dose, it is conceivable that fewer patients will experience side effects and complications.

Key facts

Study ID
NCT00247312
Run by
Schiffler Cancer Center
People needed
319
Starts
2005-10-01
Expected to finish
2015-11-01
Last updated by the study team
2015-11-17

Who can join

Age: any. Sex: male. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.